Nephrogenic systemic fibrosis.
There seems to be an association between exposure to intravenous gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF), a debilitating and sometimes fatal disease. This article addresses the relationship between GBCAs and NSF and answers some common questions. The policy deployed at Yale-New Haven Hospital for prevention of NSF and screening for patients at risk is delineated and discussed along with recommendations by the Food and Drug Administration.
Weinreb
Jeffrey C
JC
Department of Diagnostic Radiology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208042, New Haven, CT 06520-5913, USA. jeffrey.weinreb@yale.edu
Kuo
Phillip H
PH
D003287:Contrast Media / Q000009:adverse effects*; D005682:Gadolinium / Q000009:adverse effects*; D005919:Glomerular Filtration Rate; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D054989:Nephrogenic Fibrosing Dermopathy / Q000139:chemically induced* / Q000517:prevention & control*; D012307:Risk Factors
D003287:Contrast Media; D005682:Gadolinium